56,472 Shares in Penumbra, Inc. (NYSE:PEN) Acquired by WCM Investment Management LLC

WCM Investment Management LLC acquired a new stake in Penumbra, Inc. (NYSE:PEN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 56,472 shares of the company’s stock, valued at approximately $13,451,000.

Other institutional investors have also recently bought and sold shares of the company. True Wealth Design LLC acquired a new position in shares of Penumbra in the 3rd quarter valued at $26,000. GAMMA Investing LLC increased its holdings in Penumbra by 111.1% in the third quarter. GAMMA Investing LLC now owns 171 shares of the company’s stock valued at $33,000 after purchasing an additional 90 shares during the last quarter. UMB Bank n.a. lifted its stake in Penumbra by 57.4% in the fourth quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after buying an additional 70 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in Penumbra by 1,845.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 389 shares of the company’s stock worth $70,000 after buying an additional 369 shares during the last quarter. Finally, Mather Group LLC. grew its position in shares of Penumbra by 208.0% during the 4th quarter. Mather Group LLC. now owns 308 shares of the company’s stock worth $73,000 after buying an additional 208 shares during the period. Institutional investors and hedge funds own 88.88% of the company’s stock.

Insider Transactions at Penumbra

In related news, EVP Johanna Roberts sold 600 shares of the stock in a transaction on Monday, November 18th. The shares were sold at an average price of $239.74, for a total transaction of $143,844.00. Following the completion of the transaction, the executive vice president now owns 64,044 shares in the company, valued at approximately $15,353,908.56. This represents a 0.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Harpreet Grewal sold 167 shares of Penumbra stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $241.28, for a total transaction of $40,293.76. Following the completion of the sale, the director now owns 8,530 shares in the company, valued at $2,058,118.40. The trade was a 1.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,819 shares of company stock valued at $8,129,483 in the last ninety days. 5.00% of the stock is currently owned by corporate insiders.

Penumbra Stock Down 0.3 %

NYSE:PEN opened at $260.68 on Monday. The company has a market cap of $10.00 billion, a PE ratio of 303.12, a PEG ratio of 1.92 and a beta of 0.53. The stock has a 50-day simple moving average of $252.66 and a 200 day simple moving average of $221.24. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 5.82. Penumbra, Inc. has a 52-week low of $148.00 and a 52-week high of $277.89.

Analyst Ratings Changes

A number of brokerages recently weighed in on PEN. UBS Group began coverage on shares of Penumbra in a research report on Tuesday, January 21st. They issued a “buy” rating and a $305.00 price target on the stock. Robert W. Baird increased their target price on shares of Penumbra from $244.00 to $248.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Citigroup boosted their price target on shares of Penumbra from $220.00 to $245.00 and gave the company a “neutral” rating in a report on Wednesday, December 11th. Truist Financial raised their price objective on Penumbra from $240.00 to $285.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Penumbra in a report on Thursday, October 31st. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $261.36.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.